Hta Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Public, Subsidiary
- Established
- 2001-05-18
- Employees
- -
- Market Cap
- -
- Website
- https://www.atom-hitech.com
Clinical Trials
5
Active:0
Completed:2
Trial Phases
3 Phases
Phase 1:1
Phase 3:3
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Phase 3
3 (60.0%)Not Applicable
1 (20.0%)Phase 1
1 (20.0%)A Phase III Clinical Study to Compare the Safety and Efficacy of 177Lu-DOTATATE Injection and Long-acting Oxytrexine in Adult Patients With NETs
Not Applicable
Recruiting
- Conditions
- NETS Ga68 Lu177
- Interventions
- Drug: 177Lu-DOTATATE injection
- First Posted Date
- 2025-07-10
- Last Posted Date
- 2025-07-10
- Lead Sponsor
- HTA Co., Ltd.
- Target Recruit Count
- 184
- Registration Number
- NCT07057622
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
Study of 18F-Florastamin PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer
Phase 3
Recruiting
- Conditions
- Prostate Cancer
- Interventions
- Drug: Florastamin[18F] Injection
- First Posted Date
- 2024-12-31
- Last Posted Date
- 2024-12-31
- Lead Sponsor
- HTA Co., Ltd.
- Target Recruit Count
- 131
- Registration Number
- NCT06754085
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, China
A Phase I Clinical Study on the Safety and Pharmacokinetics of [18F]Florbetazine Injection
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-07-10
- Lead Sponsor
- HTA Co., Ltd.
- Target Recruit Count
- 28
- Registration Number
- NCT06593626
- Locations
- 🇨🇳
Chinese PLA General Hospital, Beijing, Beijing, China
Study of 18F-Florastamin PET/CT Imaging in Patients With at Least Intermediate Risk Prostate Cancer
- First Posted Date
- 2023-08-25
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- HTA Co., Ltd.
- Target Recruit Count
- 267
- Registration Number
- NCT06011304
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, China
Diagnostic Performance and Safety of 18F-NaF-PET/CT in Bone Metastases Compared With 99mTc⁃MDP-BS±SPECT
Phase 3
Completed
- Conditions
- Bone Metastases
- Interventions
- Drug: Sodium Fluoride F-18 Injection
- First Posted Date
- 2022-11-14
- Last Posted Date
- 2022-11-14
- Lead Sponsor
- HTA Co., Ltd.
- Target Recruit Count
- 280
- Registration Number
- NCT05614518
- Locations
- 🇨🇳
Chinese Academy of Medical Sciences Peking Union Medical College Hospital, Peking, China
News
No news found